HOME >> MEDICINE >> NEWS
No link found between pneumonitis in breast cancer patients and taxane-based chemotherapies

HOUSTON - Researchers at The University of Texas M. D. Anderson Cancer Center have shown that breast cancer patients treated with taxane-based chemotherapies and radiation are not at increased risk of developing a dangerous lung condition involving the inflammation of lung tissue, pneumonitis, according to a study published in the Nov. 17 issue of the Journal of the National Cancer Institute.

These results are vitally important, says Thomas Buchholz, M.D., the study's corresponding author, because both radiation and taxanes-based chemotherapies, including Taxotere and Taxol, have proven effective in the treatment and improved survival of selected patients with breast cancer.

In addition, these results disprove a previous smaller study that had suggested the dangerous correlation between taxanes, radiation treatment and lung injury.

"We had the unique opportunity to investigate and clearly focus on the question of whether or not taxanes increase radiation induced lung complications," says Buchholz, professor in the Department of Radiation Oncology at M. D. Anderson. "Both taxanes and radiation therapy are critically important in the treatment of patients whose disease has spread beyond the breast.

"The first study showed higher rates of toxicity and received a great deal of attention within the medical community. We were concerned that oncologists might have some reluctance in giving these appropriate treatments. With this study, we wanted to try and determine if we could alleviate the fears of both the physicians administering, and the patients receiving these potentially life-saving treatments."

The research, led by Tse-Kuan Yu, M.D., Ph.D., a resident in radiation oncology at M. D. Anderson and the study's principal investigator, analyzed 189 breast cancer patients who had been enrolled in a prospective Phase III randomized trial. The patients had received either four cycles of paclitaxel (Taxol) followed by
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
16-Nov-2004


Page: 1 2 3

Related medicine news :

1. Acupuncture found to lower elevations in blood pressure
2. Proteins found in urine of pregnant women could help diagnose preeclampsia
3. Potential drug target for treating cocaine abuse found
4. Similar results found in both older and younger patients undergoing weight-loss surgery
5. Infectious agent linked to mad cow disease found in organs other than the brain
6. Generation gap found in chronic pain
7. A site for sore eyes: New target for allergies found under the eyelid
8. Chemicals found in cherries may help fight diabetes
9. Thanks for the memories: cinematic portrayal of amnesia is profoundly misleading
10. Very high prevalence of virus linked to cervical cancer found in adolescent women
11. Two-fisted assault on dopamine transport system may be foundation of Parkinsons disease

Post Your Comments:
(Date:7/30/2015)... ... 30, 2015 , ... Zaca Life has created Recovery Chewable ... water needed, the refreshing berry-flavored tablets are the perfect travel companion. , “We ... that may help with body detoxification, protection and hydration,” said Mark Aleks, Zaca ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine Association (ATA) ... Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to attract ... take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. Michael ... Care Administrator. Dr. Demoratz is a strong proponent of early access to palliative ...
(Date:7/30/2015)... ... 2015 , ... The Beryl Institute announces its sixth annual ... Patient Experience Institute, these offerings reinforce the commitment to help frame and expand ... the experience movement, and provide information and research to support expanded focus and ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied Research ... Patient Registry Act of 2015’. The bill was introduced in Congress yesterday by ... Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2
(Date:7/29/2015)... July 30, 2015 Roche (SIX: RO, ROG; ... cobas® EGFR Mutation Test v2 for Premarket Approval ... (FDA), as a companion diagnostic test for AZD9291, ... cancer patients with an acquired resistant mutation.  ... who have adenocarcinoma with tumor containing an EGFR ...
(Date:7/29/2015)... 2015  Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... and supplier of injectable drug delivery systems, today announced ... the Company with flexibility and control to support its ... an equity purchase agreement for up to $45 million ... Chicago -based institutional investor, which provides the ...
(Date:7/29/2015)... BERKELEY, Calif. , July 29, 2015 /PRNewswire/ ... of the Daiichi Sankyo Group, announced today that ... clinical trial results demonstrating that the investigational drug, PLX3397, ... in most patients with tenosynovial giant cell tumor (TGCT), ... tendon sheath. Following phase 1 dose-escalation, which ...
Breaking Medicine Technology:Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 2Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 3Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5
Cached News: